Global Irritable Bowel Syndrome (IBS) Therapeutics Market 2020 - Research Report, Demand, Price, By Application, Region and Forecast to 2026

 Published Date : Oct-2018   |    Format :PDF |    Number of Pages : 90   |    Publisher : e-Market Research

This report studies the global market size of Irritable Bowel Syndrome (IBS) Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Irritable Bowel Syndrome (IBS) Therapeutics in these regions.
This research report categorizes the global Irritable Bowel Syndrome (IBS) Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time.
In 2017, the global Irritable Bowel Syndrome (IBS) Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Irritable Bowel Syndrome (IBS) Therapeutics market based on company, product type, application and key regions.

The various contributors involved in the value chain of Irritable Bowel Syndrome (IBS) Therapeutics include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Irritable Bowel Syndrome (IBS) Therapeutics include
    Abbott Laboratories
    Synergy Pharmaceuticals
    Sucampo Pharmaceuticals
    Valeant Pharmaceuticals International
    Ardelyx
    Astellas Pharma
    Novartis
    GlaxoSmithKline
    Ironwood Pharmaceuticals

Market Size Split by Type
    Blautix (Strain)
    Bekinda (IBS-D)
    SYN-010
    Tenapanor
Market Size Split by Application
    Hospital
    Research

Market size split by Region
    North America
        United States
        Canada
        Mexico
    Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Malaysia
        Philippines
        Thailand
        Vietnam
    Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
    Central & South America
        Brazil
        Rest of Central & South America
    Middle East & Africa
        GCC Countries
        Turkey
        Egypt
        South Africa

The study objectives of this report are:
    To study and analyze the global Irritable Bowel Syndrome (IBS) Therapeutics market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
    To understand the structure of Irritable Bowel Syndrome (IBS) Therapeutics market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Irritable Bowel Syndrome (IBS) Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Irritable Bowel Syndrome (IBS) Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
    To project the value and volume of Irritable Bowel Syndrome (IBS) Therapeutics submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Irritable Bowel Syndrome (IBS) Therapeutics are as follows:
    History Year: 2013-2017
    Base Year: 2017
    Estimated Year: 2018
    Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Irritable Bowel Syndrome (IBS) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

1 Study Coverage
    1.1  Irritable Bowel Syndrome (IBS) Therapeutics Product
    1.2 Key Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
        1.4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size Growth Rate by Type
        1.4.2 Blautix (Strain)
        1.4.3 Bekinda (IBS-D)
        1.4.4 SYN-010
        1.4.5 Tenapanor
    1.5 Market by Application
        1.5.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size Growth Rate by Application
        1.5.2 Hospital
        1.5.3 Research
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size
        2.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue 2016-2025
        2.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales 2016-2025
    2.2 Irritable Bowel Syndrome (IBS) Therapeutics Growth Rate by Regions
        2.2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Regions
        2.2.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Regions

3 Breakdown Data by Manufacturers
    3.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers
        3.1.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers
        3.1.2 Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Manufacturers
        3.1.3 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Concentration Ratio (CR5 and HHI)
    3.2 Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Manufacturers
        3.2.1 Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Manufacturers (2016-2018)
        3.2.2 Irritable Bowel Syndrome (IBS) Therapeutics Revenue Share by Manufacturers (2016-2018)
    3.3 Irritable Bowel Syndrome (IBS) Therapeutics Price by Manufacturers
    3.4 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturing Base Distribution, Product Types
        3.4.1 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Irritable Bowel Syndrome (IBS) Therapeutics Product Category
        3.4.3 Date of International Manufacturers Enter into Irritable Bowel Syndrome (IBS) Therapeutics  Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
    4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type
    4.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Type
    4.3 Irritable Bowel Syndrome (IBS) Therapeutics Price by Type

5 Breakdown Data by Application
    5.1 Overview
    5.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Application

6 North America
    6.1 North America Irritable Bowel Syndrome (IBS) Therapeutics by Countries
        6.1.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
        6.1.2 North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
        6.1.3 United States
        6.1.4 Canada
        6.1.5 Mexico
    6.2 North America Irritable Bowel Syndrome (IBS) Therapeutics by Type
    6.3 North America Irritable Bowel Syndrome (IBS) Therapeutics by Application
    6.4 North America Irritable Bowel Syndrome (IBS) Therapeutics by Company

7 Europe
    7.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Countries
        7.1.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
        7.1.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
        7.1.3 Germany
        7.1.4 France
        7.1.5 UK
        7.1.6 Italy
        7.1.7 Russia
    7.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Type
    7.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Application
    7.4 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Company

8 Asia Pacific
    8.1 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Countries
        8.1.1 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
        8.1.2 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
        8.1.3 China
        8.1.4 Japan
        8.1.5 Korea
        8.1.6 India
        8.1.7 Australia
        8.1.8 Indonesia
        8.1.9 Malaysia
        8.1.10 Philippines
        8.1.11 Thailand
        8.1.12 Vietnam
        8.1.13 Singapore
    8.2 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Type
    8.3 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Application
    8.4 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Company

9 Central & South America
    9.1 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by Countries
        9.1.1 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
        9.1.2 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
        9.1.3 Brazil
    9.2 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by Type
    9.3 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by Application
    9.4 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by Company

10 Middle East and Africa
    10.1 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Countries
        10.1.1 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
        10.1.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
        10.1.3 GCC Countries
        10.1.4 Turkey
        10.1.5 Egypt
        10.1.6 South Africa
    10.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Type
    10.3 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Application
    10.4 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Company

11 Company Profiles
    11.1 Abbott Laboratories
        11.1.1 Abbott Laboratories Company Details
        11.1.2 Company Description
        11.1.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.1.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.1.5 Recent Development
    11.2 Synergy Pharmaceuticals
        11.2.1 Synergy Pharmaceuticals Company Details
        11.2.2 Company Description
        11.2.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.2.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.2.5 Recent Development
    11.3 Sucampo Pharmaceuticals
        11.3.1 Sucampo Pharmaceuticals Company Details
        11.3.2 Company Description
        11.3.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.3.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.3.5 Recent Development
    11.4 Valeant Pharmaceuticals International
        11.4.1 Valeant Pharmaceuticals International Company Details
        11.4.2 Company Description
        11.4.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.4.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.4.5 Recent Development
    11.5 Ardelyx
        11.5.1 Ardelyx Company Details
        11.5.2 Company Description
        11.5.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.5.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.5.5 Recent Development
    11.6 Astellas Pharma
        11.6.1 Astellas Pharma Company Details
        11.6.2 Company Description
        11.6.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.6.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.6.5 Recent Development
    11.7 Novartis
        11.7.1 Novartis Company Details
        11.7.2 Company Description
        11.7.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.7.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.7.5 Recent Development
    11.8 GlaxoSmithKline
        11.8.1 GlaxoSmithKline Company Details
        11.8.2 Company Description
        11.8.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.8.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.8.5 Recent Development
    11.9 Ironwood Pharmaceuticals
        11.9.1 Ironwood Pharmaceuticals Company Details
        11.9.2 Company Description
        11.9.3 Sales, Revenue and Gross Margin of Irritable Bowel Syndrome (IBS) Therapeutics
        11.9.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Description
        11.9.5 Recent Development

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    12.1 Market Opportunities and Drivers
    12.2 Market Challenges
    12.3 Market Risks/Restraints
    12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis
    13.1 Value Chain Analysis
        13.1.1 Typical Suppliers of Key Irritable Bowel Syndrome (IBS) Therapeutics Raw Material
        13.1.2 Irritable Bowel Syndrome (IBS) Therapeutics Customers
    13.2 Sales Channels Analysis
        13.2.1 Sales Channels Analysis
        13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
            15.1.1.1 Research Programs/Design
            15.1.1.2 Market Size Estimation
            15.1.1.3 Market Breakdown and Data Triangulation
        15.1.2 Data Source
            15.1.2.1 Secondary Sources
            15.1.2.2 Primary Sources
    15.2 Author Details
    15.3 Disclaimer



List of Tables and Figures

    Figure Picture of Irritable Bowel Syndrome (IBS) Therapeutics
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Production (K Units) and CAGR (%) Comparison by Types (Product Category) (2013-2025)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Production Market Share by Types (Product Category) in 2017
    Figure Blautix (Strain) Product Picture
    Table Major Manufacturers of Blautix (Strain)
    Figure Bekinda (IBS-D) Product Picture
    Table Major Manufacturers of Bekinda (IBS-D)
    Figure SYN-010 Product Picture
    Table Major Manufacturers of SYN-010
    Figure Tenapanor Product Picture
    Table Major Manufacturers of Tenapanor
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size Growth Rate by Application 2018-2025 (K Units)
    Figure Hospital
    Figure Research
    Figure Irritable Bowel Syndrome (IBS) Therapeutics Report Years Considered
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size 2016-2025 (Million US$)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Sales 2016-2025 (K Units)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size by Regions 2016-2025 (K Units) & (Million US$)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Regions 2016-2025 (K Units)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Regions 2016-2025
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Regions 2016-2025
    Figure 2017 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Regions
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Regions 2016-2025 (Million US$)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Regions 2016-2025
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Regions 2016-2025
    Figure 2017 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Regions
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers (2016-2018) (K Units)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Share by Manufacturers (2016-2018)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Share by Manufacturers in 2017
    Table Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Manufacturers (2016-2018) (Million US$)
    Table Irritable Bowel Syndrome (IBS) Therapeutics Revenue Share by Manufacturers (2016-2018)
    Figure Irritable Bowel Syndrome (IBS) Therapeutics Value Share by Manufacturers in 2017
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table Key Manufacturers Irritable Bowel Syndrome (IBS) Therapeutics Price (2016-2018) (USD/Unit)
    Table Irritable Bowel Syndrome (IBS) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
    Table Manufacturers Irritable Bowel Syndrome (IBS) Therapeutics Product Category
    Table Date of International Manufacturers Enter into Irritable Bowel Syndrome (IBS) Therapeutics Market
    Table Manufacturers Mergers & Acquisitions, Expansion Plans
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type (2016-2025) (K Units)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Share by Type (2016-2025)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type (2016-2025)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type in 2017
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Type (2016-2025) (Million US$)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Share by Type (2016-2025)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Type (2016-2025)
    Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Type in 2017
    Table Irritable Bowel Syndrome (IBS) Therapeutics Price by Type 2013-2018 (USD/Unit)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application (2016-2025) (K Units)
    Table Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Share by Application (2016-2025)
    Figure Global Sales Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application (2016-2025)
    Figure Global Sales Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application (2016-2025)
    Figure North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate 2016-2025 (K Units)
    Figure North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries (2016-2025) (K Units)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries (2016-2025)
    Figure 2017 North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries (2016-2025) (Million US$)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries (2016-2025)
    Figure 2017 North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries
    Figure United States Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure United States Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Canada Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Canada Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Mexico Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Mexico Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type (2016-2025) (K Units)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type (2016-2025)
    Figure 2017 North America Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Type
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application (2016-2025) (K Units)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Application (2016-2025)
    Figure 2017 North America Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Company (2016-2018) (K Units)
    Table North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company (2016-2018)
    Figure North America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company in 2017
    Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate 2016-2025 (K Units)
    Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries (2016-2025) (K Units)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries (2016-2025)
    Figure 2017 Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries (2016-2025) (Million US$)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries (2016-2025)
    Figure 2017 Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries
    Figure Germany Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Germany Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (K Units)
    Figure France Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure France Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (K Units)
    Figure UK Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure UK Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Italy Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Italy Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Russia Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Russia Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type (2016-2025) (K Units)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type (2016-2025)
    Figure 2017 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Type
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application (2016-2025) (K Units)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Application (2016-2025)
    Figure 2017 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales by Company (2016-2018) (K Units)
    Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company (2016-2018)
    Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company in 2017
    Figure Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate 2016-2025 (K Units)
    Figure Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries (2016-2025) (K Units)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries (2016-2025)
    Figure 2017 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries (2016-2025) (Million US$)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries (2016-2025)
    Figure 2017 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries
    Figure China Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure China Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Japan Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Japan Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Korea Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Korea Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure India Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure India Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Australia Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Australia Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Indonesia Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Indonesia Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Malaysia Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Malaysia Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Philippines Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Philippines Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Thailand Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Thailand Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Vietnam Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Vietnam Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Singapore Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Singapore Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type (2016-2025) (K Units)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type (2016-2025)
    Figure 2017 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Type
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application (2016-2025) (K Units)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Application (2016-2025)
    Figure 2017 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales by Company (2016-2018) (K Units)
    Table Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company (2016-2018)
    Figure Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company in 2017
    Figure Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate 2016-2025 (K Units)
    Figure Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries (2016-2025) (K Units)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries (2016-2025)
    Figure 2017 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries (2016-2025) (Million US$)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries (2016-2025)
    Figure 2017 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries
    Figure Brazil Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Brazil Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Argentina Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Argentina Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type (2016-2025) (K Units)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type (2016-2025)
    Figure 2017 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Type
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application (2016-2025) (K Units)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Application (2016-2025)
    Figure 2017 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Company (2016-2018) (K Units)
    Table Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company (2016-2018)
    Figure Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company in 2017
    Figure Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate 2016-2025 (K Units)
    Figure Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries (2016-2025) (K Units)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries (2016-2025)
    Figure 2017 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Countries
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries (2016-2025) (Million US$)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries (2016-2025)
    Figure 2017 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Countries
    Figure GCC Countries Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure GCC Countries Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Turkey Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Turkey Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure Egypt Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure Egypt Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Figure South Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Growth Rate (2016-2025) (K Units)
    Figure South Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales by Type (2016-2025) (K Units)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type (2016-2025)
    Figure 2017 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Type
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application (2016-2025) (K Units)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Application (2016-2025)
    Figure 2017 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales by Company (2016-2018) (K Units)
    Table Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company (2016-2018)
    Figure Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Company in 2017
    Table Abbott Laboratories Company Details
    Table Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Abbott Laboratories Recent Development
    Table Synergy Pharmaceuticals Company Details
    Table Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Synergy Pharmaceuticals Recent Development
    Table Sucampo Pharmaceuticals Company Details
    Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Sucampo Pharmaceuticals Recent Development
    Table Valeant Pharmaceuticals International Company Details
    Table Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Valeant Pharmaceuticals International Recent Development
    Table Ardelyx Company Details
    Table Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Ardelyx Recent Development
    Table Astellas Pharma Company Details
    Table Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Astellas Pharma Recent Development
    Table Novartis Company Details
    Table Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Novartis Recent Development
    Table GlaxoSmithKline Company Details
    Table GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table GlaxoSmithKline Recent Development
    Table Ironwood Pharmaceuticals Company Details
    Table Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Ironwood Pharmaceuticals Recent Development
    Figure GDP by Regions / Largest Economies Pie Chart in 2016
    Figure G20 GDP Long-Term Forecast Total, Million US dollars, 2060
    Figure G20 Gross Domestic Product (GDP)Total, US Dollars/Capita, 2016
    Figure Saving Rate Total, % of GDP, 2015
    Table Irritable Bowel Syndrome (IBS) Therapeutics Value Chain
    Table Typical Suppliers of Key Irritable Bowel Syndrome (IBS) Therapeutics Raw Material
    Table Irritable Bowel Syndrome (IBS) Therapeutics Customers List
    Table Irritable Bowel Syndrome (IBS) Therapeutics Sales Channels
    Table Irritable Bowel Syndrome (IBS) Therapeutics Distributors List
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources

 Select a Format



 Buy Now

24/7 Customer Support

Have questions?

Direct
+1-386-310-3803
Toll Free
+1-855-465-4651
sales@e-marketresearch.com